



Reprinted
January 30, 2014

HOUSE BILL No. 1218

DIGEST OF HB 1218 (Updated January 29, 2014 6:11 pm - DI 77)

Citations Affected: IC 12-7; IC 12-23; IC 35-48; noncode.

Synopsis: Drug treatment and reporting. Requires the division of mental health and addiction (division) to establish standards and protocols for opioid treatment programs to do the following: (1) Assess new opioid treatment program patients to determine the most effective opioid treatment medications to start the patient's opioid treatment. (2) Ensure that patients voluntarily choose maintenance treatment and that the treatment be explained to the patient. (3) Transition appropriate opioid treatment program patients who are receiving methadone for opioid treatment to other approved opioid treatment medications. Requires an opioid treatment program to follow the standards and protocols adopted by the division for each opioid treatment program patient. Provides a list of the drugs that may be used by an opioid treatment program as an alternative for methadone. Requires the dispenser at an opioid treatment program to transmit certain information to the division. Provides that the information is subject to federal patient confidentiality regulations. Requires that the board of pharmacy (board) adopt a rule requiring a practitioner and a opioid treatment program to check the Indiana scheduled prescription electronic collection and tracking (INSPECT) program before initially prescribing a controlled substance and periodically during the course of treatment that uses a controlled substance. Requires the division to
(Continued next page)

Effective: Upon passage; July 1, 2014.

Davisson, Clere

January 14, 2014, read first time and referred to Committee on Public Health.
January 23, 2014, amended, reported — Do Pass.
January 29, 2014, read second time, amended, ordered engrossed.

HB 1218—LS 6952/DI 77



Digest Continued

report on the information collected. Increases the penalty to a Level 6 felony for violations of the central repository for controlled substances data laws. Provides that beginning July 1, 2015, the board shall provide for the modification of the controlled substance prescription monitoring program to: (1) accept prescription drug information; and (2) monitor all prescription drugs; in the same manner as controlled substances. Provides that beginning July 1, 2015, any person who is required by the central repository for controlled substances data law to transmit controlled substance information to the INSPECT program must submit all prescription drug information to the INSPECT program in the same manner as controlled substance information is transmitted. Provides that the prescription drug information is confidential and may not be released to a law enforcement officer or law enforcement agency, except for controlled substances. Provides that the board may not require submission of noncontrolled substance prescription information until the professional licensing agency certifies the security of the INSPECT program. Requires the health finance commission to study the security of the INSPECT program. (The introduced version of this bill was prepared by the commission on mental health and addiction.)

HB 1218—LS 6952/DI 77



Reprinted
January 30, 2014

Second Regular Session 118th General Assembly (2014)

PRINTING CODE. Amendments: Whenever an existing statute (or a section of the Indiana Constitution) is being amended, the text of the existing provision will appear in this style type, additions will appear in **this style type**, and deletions will appear in ~~this style type~~.

Additions: Whenever a new statutory provision is being enacted (or a new constitutional provision adopted), the text of the new provision will appear in **this style type**. Also, the word **NEW** will appear in that style type in the introductory clause of each SECTION that adds a new provision to the Indiana Code or the Indiana Constitution.

Conflict reconciliation: Text in a statute in *this style type* or ~~this style type~~ reconciles conflicts between statutes enacted by the 2013 Regular Session and 2013 First Regular Technical Session of the General Assembly.

HOUSE BILL No. 1218

A BILL FOR AN ACT to amend the Indiana Code concerning human services.

Be it enacted by the General Assembly of the State of Indiana:

- 1 SECTION 1. IC 12-7-2-67.5 IS ADDED TO THE INDIANA CODE
2 AS A **NEW SECTION** TO READ AS FOLLOWS [EFFECTIVE JULY
3 1, 2014]: **Sec. 67.5. "Dispense", for purposes of IC 12-23-18-8, has**
4 **the meaning set forth in IC 12-23-18-8(a).**
5 SECTION 2. IC 12-23-18-7 IS ADDED TO THE INDIANA CODE
6 AS A **NEW SECTION** TO READ AS FOLLOWS [EFFECTIVE JULY
7 1, 2014]: **Sec. 7. (a) The division shall adopt rules under IC 4-22-2**
8 **to establish standards and protocols for opioid treatment programs**
9 **to do the following:**
10 (1) **Assess new opioid treatment program patients to**
11 **determine the most effective opioid treatment medications to**
12 **start the patient's opioid treatment.**
13 (2) **Ensure that each patient voluntarily chooses maintenance**
14 **treatment and that relevant facts concerning the use of opioid**

HB 1218—LS 6952/DI 77



- 1 treatment medications are clearly and adequately explained
 2 to the patient.
- 3 (3) Have appropriate opioid treatment program patients who
 4 are receiving methadone for opioid treatment move to
 5 receiving other approved opioid treatment medications.
- 6 (b) An opioid treatment program shall follow the standards and
 7 protocols adopted under subsection (a) for each opioid treatment
 8 program patient.
- 9 (c) Subject to subsection (a), an opioid treatment program may
 10 use any of the following medications as an alternative for
 11 methadone for opioid treatment:
- 12 (1) Buprenorphine.
- 13 (2) Buprenorphine combination products containing
 14 naloxone.
- 15 (3) Any other medication that has been approved by:
- 16 (A) the federal Food and Drug Administration for use in
 17 the treatment of opioid addiction; and
- 18 (B) the division under subsection (e).
- 19 (d) Before starting a patient on a new opioid treatment
 20 medication, the opioid treatment program shall explain to the
 21 patient the potential side effects of the new medication.
- 22 (e) The division may adopt rules under IC 4-22-2 to provide for
 23 other medications as alternatives to methadone that may be used
 24 under subsection (a).
- 25 SECTION 3. IC 12-23-18-8 IS ADDED TO THE INDIANA CODE
 26 AS A NEW SECTION TO READ AS FOLLOWS [EFFECTIVE JULY
 27 1, 2014]: Sec. 8. (a) As used in this section, "dispense" means to
 28 deliver a controlled substance to an ultimate user.
- 29 (b) Subject to the federal patient confidentiality requirements
 30 under 42 CFR Part 2, when an opioid treatment program dispenses
 31 a controlled substance designated by the Indiana board of
 32 pharmacy under IC 35-48-2-5 through 35-48-2-10, the opioid
 33 treatment program shall provide the following information upon
 34 request from the division:
- 35 (1) The medications dispensed by the program.
- 36 (2) The medication delivery process, which includes whether
 37 the medication was in liquid, film, or another form.
- 38 (3) The number of doses dispensed of each medication.
- 39 (4) The dosage quantities for each medication.
- 40 (5) The number of patients receiving take home medications.
- 41 (6) The number of days of supply dispensed.
- 42 (7) Patient demographic information for each medication,



1 including gender, age, and time in treatment.

2 (8) The dispenser's United States Drug Enforcement Agency
3 registration number.

4 (c) An opioid treatment program is required to provide the
5 information required under this section to the division in a manner
6 prescribed by the division.

7 (d) The division shall annually report the information collected
8 under this section to the:

9 (1) commission on mental health and addiction; and

10 (2) health finance committee.

11 SECTION 4. IC 35-48-7-8.1, AS AMENDED BY P.L.152-2012,
12 SECTION 14, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE
13 UPON PASSAGE]: Sec. 8.1. (a) The board shall provide for a
14 controlled substance prescription monitoring program that includes the
15 following components:

16 (1) Each time a controlled substance designated by the board
17 under IC 35-48-2-5 through IC 35-48-2-10 is dispensed, the
18 dispenser shall transmit to the INSPECT program the following
19 information:

20 (A) The controlled substance recipient's name.

21 (B) The controlled substance recipient's or the recipient
22 representative's identification number or the identification
23 number or phrase designated by the INSPECT program.

24 (C) The controlled substance recipient's date of birth.

25 (D) The national drug code number of the controlled substance
26 dispensed.

27 (E) The date the controlled substance is dispensed.

28 (F) The quantity of the controlled substance dispensed.

29 (G) The number of days of supply dispensed.

30 (H) The dispenser's United States Drug Enforcement Agency
31 registration number.

32 (I) The prescriber's United States Drug Enforcement Agency
33 registration number.

34 (J) An indication as to whether the prescription was
35 transmitted to the pharmacist orally or in writing.

36 (K) Other data required by the board.

37 (2) The information required to be transmitted under this section
38 must be transmitted not more than seven (7) days after the date on
39 which a controlled substance is dispensed. **However,**
40 **notwithstanding any other provision of this section,**
41 **beginning:**

42 (A) July 1, 2015, the information required to be



1 **transmitted under this section must be transmitted not**
 2 **more than three (3) days after the date on which a**
 3 **controlled substance is dispensed; and**

4 **(B) January 1, 2016, the information required to be**
 5 **transmitted under this section must be transmitted not**
 6 **more than twenty-four (24) hours after the date on which**
 7 **a controlled substance is dispensed.**

8 (3) A dispenser shall transmit the information required under this
 9 section by:

10 (A) uploading to the INSPECT web site;

11 (B) a computer diskette; or

12 (C) a CD-ROM disk;

13 that meets specifications prescribed by the board.

14 (4) The board may require that prescriptions for controlled
 15 substances be written on a one (1) part form that cannot be
 16 duplicated. However, the board may not apply such a requirement
 17 to prescriptions filled at a pharmacy with a Category II permit (as
 18 described in IC 25-26-13-17) and operated by a hospital licensed
 19 under IC 16-21, or prescriptions ordered for and dispensed to
 20 bona fide enrolled patients in facilities licensed under IC 16-28.
 21 The board may not require multiple copy prescription forms for
 22 any prescriptions written. The board may not require different
 23 prescription forms for any individual drug or group of drugs.
 24 Prescription forms required under this subdivision must be
 25 approved by the Indiana board of pharmacy established by
 26 IC 25-26-13-3.

27 (5) The costs of the program.

28 (b) This subsection applies only to a retail pharmacy. A pharmacist,
 29 pharmacy technician, or person authorized by a pharmacist to dispense
 30 a controlled substance may not dispense a controlled substance to a
 31 person who is not personally known to the pharmacist, pharmacy
 32 technician, or person authorized by a pharmacist to dispense a
 33 controlled substance unless the person taking possession of the
 34 controlled substance provides documented proof of the person's
 35 identification to the pharmacist, pharmacy technician, or person
 36 authorized by a pharmacist to dispense a controlled substance.

37 SECTION 5. IC 35-48-7-11.1, AS AMENDED BY P.L.84-2010,
 38 SECTION 99, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE
 39 UPON PASSAGE]: Sec. 11.1. (a) Information received by the
 40 INSPECT program under section 8.1 of this chapter is confidential.

41 (b) The board shall carry out a program to protect the confidentiality
 42 of the information described in subsection (a). The board may disclose



- 1 the information to another person only under subsection (c), (d), or (g).
 2 (c) The board may disclose confidential information described in
 3 subsection (a) to any person who is authorized to engage in receiving,
 4 processing, or storing the information.
 5 (d) Except as provided in subsections (e) and (f), the board may
 6 release confidential information described in subsection (a) to the
 7 following persons:
 8 (1) A member of the board or another governing body that
 9 licenses practitioners and is engaged in an investigation, an
 10 adjudication, or a prosecution of a violation under any state or
 11 federal law that involves a controlled substance.
 12 (2) An investigator for the consumer protection division of the
 13 office of the attorney general, a prosecuting attorney, the attorney
 14 general, a deputy attorney general, or an investigator from the
 15 office of the attorney general, who is engaged in:
 16 (A) an investigation;
 17 (B) an adjudication; or
 18 (C) a prosecution;
 19 of a violation under any state or federal law that involves a
 20 controlled substance.
 21 (3) A law enforcement officer who is an employee of:
 22 (A) a local, state, or federal law enforcement agency; or
 23 (B) an entity that regulates controlled substances or enforces
 24 controlled substances rules or laws in another state;
 25 that is certified to receive **controlled substance prescription**
 26 **drug** information from the INSPECT program.
 27 (4) A practitioner or practitioner's agent certified to receive
 28 information from the INSPECT program.
 29 (5) A controlled substance monitoring program in another state
 30 with which Indiana has established an interoperability agreement.
 31 (6) The state toxicologist.
 32 (7) A certified representative of the Medicaid retrospective and
 33 prospective drug utilization review program.
 34 (8) A substance abuse assistance program for a licensed health
 35 care provider who:
 36 (A) has prescriptive authority under IC 25; and
 37 (B) is participating in the assistance program.
 38 (e) Information provided to an individual under:
 39 (1) subsection (d)(3) is limited to information:
 40 (A) concerning an individual or proceeding involving the
 41 unlawful diversion or misuse of a schedule II, III, IV, or V
 42 controlled substance; and



- 1 (B) that will assist in an investigation or proceeding; and
 2 (2) subsection (d)(4) may be released only for the purpose of:
 3 (A) providing medical or pharmaceutical treatment; or
 4 (B) evaluating the need for providing medical or
 5 pharmaceutical treatment to a patient.
- 6 (f) Before the board releases confidential information under
 7 subsection (d), the applicant must be approved by the INSPECT
 8 program in a manner prescribed by the board.
- 9 (g) The board may release to:
 10 (1) a member of the board or another governing body that licenses
 11 practitioners;
 12 (2) an investigator for the consumer protection division of the
 13 office of the attorney general, a prosecuting attorney, the attorney
 14 general, a deputy attorney general, or an investigator from the
 15 office of the attorney general; or
 16 (3) a law enforcement officer who is:
 17 (A) authorized by the state police department to receive ~~the~~
 18 ~~type of controlled substance prescription drug~~ information;
 19 ~~released;~~ and
 20 (B) approved by the board to receive the type of information
 21 released;
 22 confidential information generated from computer records that
 23 identifies practitioners who are prescribing or dispensing large
 24 quantities of a controlled substance.
- 25 (h) The information described in subsection (g) may not be released
 26 until it has been reviewed by:
 27 (1) a member of the board who is licensed in the same profession
 28 as the prescribing or dispensing practitioner identified by the data;
 29 or
 30 (2) the board's designee;
 31 and until that member or the designee has certified that further
 32 investigation is warranted. However, failure to comply with this
 33 subsection does not invalidate the use of any evidence that is otherwise
 34 admissible in a proceeding described in subsection (i).
- 35 (i) An investigator or a law enforcement officer receiving
 36 confidential information under subsection (c), (d), or (g) may disclose
 37 the information to a law enforcement officer or an attorney for the
 38 office of the attorney general for use as evidence in the following:
 39 (1) A proceeding under IC 16-42-20.
 40 (2) A proceeding under any state or federal law that involves a
 41 controlled substance.
 42 (3) A criminal proceeding or a proceeding in juvenile court that



1 involves a controlled substance.

2 (j) The board may compile statistical reports from the information
3 described in subsection (a). The reports must not include information
4 that identifies any practitioner, ultimate user, or other person
5 administering a controlled substance. Statistical reports compiled under
6 this subsection are public records.

7 (k) **Except as provided in IC 25-22.5-13**, this section may not be
8 construed to require a practitioner to obtain information about a patient
9 from the data base.

10 (l) A practitioner is immune from civil liability for an injury, death,
11 or loss to a person solely due to a practitioner seeking or not seeking
12 information from the INSPECT program. The civil immunity described
13 in this subsection does not extend to a practitioner if the practitioner
14 receives information directly from the INSPECT program and then
15 negligently misuses this information. This subsection does not apply to
16 an act or omission that is a result of gross negligence or intentional
17 misconduct.

18 (m) The board may review the records of the INSPECT program. If
19 the board determines that a violation of the law may have occurred, the
20 board shall notify the appropriate law enforcement agency or the
21 relevant government body responsible for the licensure, regulation, or
22 discipline of practitioners authorized by law to prescribe controlled
23 substances.

24 (n) A practitioner who in good faith discloses information based on
25 a report from the INSPECT program to a law enforcement agency is
26 immune from criminal or civil liability. A practitioner that discloses
27 information to a law enforcement agency under this subsection is
28 presumed to have acted in good faith.

29 SECTION 6. IC 35-48-7-12.1, AS AMENDED BY P.L.42-2011,
30 SECTION 77, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE
31 JULY 1, 2014]: Sec. 12.1. (a) The board shall adopt rules under
32 IC 4-22-2 to implement this chapter, including the following:

33 (1) Information collection and retrieval procedures for the
34 INSPECT program, including the controlled substances to be
35 included in the program required under section 8.1 of this chapter.

36 (2) Design for the creation of the data base required under section
37 10.1 of this chapter.

38 (3) Requirements for the development and installation of online
39 electronic access by the board to information collected by the
40 INSPECT program.

41 (4) Identification of emergency situations or other circumstances
42 in which a practitioner may prescribe, dispense, and administer a



1 prescription drug specified in section 8.1 of this chapter without
 2 a written prescription or on a form other than a form specified in
 3 section 8.1(a)(4) of this chapter.

4 **(5) Requirements for a practitioner and an opioid treatment**
 5 **program operating under IC 12-23-18 to check the INSPECT**
 6 **program:**

7 **(A) before initially prescribing a controlled substance to a**
 8 **patient; and**

9 **(B) periodically during the course of treatment that uses a**
 10 **controlled substance.**

11 (b) The board may:

12 (1) set standards for education courses for individuals authorized
 13 to use the INSPECT program;

14 (2) identify treatment programs for individuals addicted to
 15 controlled substances monitored by the INSPECT program; and

16 (3) work with impaired practitioner associations to provide
 17 intervention and treatment.

18 SECTION 7. IC 35-48-7-14 IS AMENDED TO READ AS
 19 FOLLOWS [EFFECTIVE JULY 1, 2014]: Sec. 14. A person who
 20 knowingly or intentionally violates this chapter commits a ~~Class A~~
 21 ~~misdemeanor.~~ **Level 6 felony.**

22 SECTION 8. IC 35-48-7-16 IS ADDED TO THE INDIANA CODE
 23 AS A NEW SECTION TO READ AS FOLLOWS [EFFECTIVE JULY
 24 1, 2014]: **Sec. 16. (a) Notwithstanding any other provision of this**
 25 **chapter, beginning January 1, 2015, the board shall provide for the**
 26 **modification of the controlled substance prescription monitoring**
 27 **program to:**

28 **(1) accept prescription drug information; and**

29 **(2) monitor all prescription drugs;**

30 **in the same manner as controlled substances. However, the board**
 31 **shall take into account that a dispenser does not collect the same**
 32 **information for a noncontrolled substance prescription and a**
 33 **controlled substance prescription, and the board may not require**
 34 **a pharmacy to collect additional information and submit**
 35 **information for a noncontrolled substance prescription unless the**
 36 **information is typically collected by a dispenser.**

37 **(b) Notwithstanding any other provision of this chapter,**
 38 **beginning July 1, 2015, any person who is required to transmit**
 39 **controlled substance information to the INSPECT program under**
 40 **this chapter must submit all prescription drug information to the**
 41 **INSPECT program in the same manner as controlled substance**
 42 **information is transmitted.**



1 (c) Notwithstanding any other provision of this chapter,
2 beginning July 1, 2015, the information required to be transmitted
3 under this section must be transmitted not more than three (3)
4 days after the date on which a prescription drug is dispensed.

5 (d) Notwithstanding any other provision of this chapter,
6 beginning January 1, 2016, the information required to be
7 transmitted under this section must be transmitted not more than
8 twenty-four (24) hours after the date on which a prescription drug
9 is dispensed.

10 (e) Prescription drug information collected under this section is
11 subject to the confidentiality requirements under section 11.1 of
12 this chapter. However, prescription drug information, except for
13 controlled substances, may not be released to a law enforcement
14 officer or law enforcement agency.

15 (f) This section does not apply to a facility licensed under
16 IC 16-28 or a hospital licensed under IC 16-21 that is not required
17 to submit prescription information under section 8.1(a)(4) of this
18 chapter.

19 (g) Before January 1, 2015, the Indiana professional licensing
20 agency shall study and analyze the integrity and security of the
21 INSPECT program concerning all controlled substances required
22 to be reported to the INSPECT program. Notwithstanding any
23 other provision of this section, if the Indiana professional licensing
24 agency is unable to certify the integrity and security of the
25 INSPECT program before January 1, 2015, the board may not
26 accept noncontrolled substance prescription information or
27 require the submission of noncontrolled substance prescription
28 information until the Indiana professional licensing agency
29 certifies to the board the integrity and security of the INSPECT
30 program.

31 SECTION 9. [EFFECTIVE JULY 1, 2014] (a) During the 2014
32 interim of the general assembly, the health finance commission
33 (IC 2-5-23) shall study the integrity and security of the INSPECT
34 program (IC 35-48-7). The commission shall make findings and
35 recommendations, including recommendations to the Indiana
36 professional licensing agency established by IC 25-1-5-3 to ensure
37 that data collected by the INSPECT program may be used only for
38 lawful purposes.

39 (b) This SECTION expires January 1, 2015.

40 SECTION 10. An emergency is declared for this act.



COMMITTEE REPORT

Mr. Speaker: Your Committee on Public Health, to which was referred House Bill 1218, has had the same under consideration and begs leave to report the same back to the House with the recommendation that said bill be amended as follows:

Page 3, delete lines 12 through 42, begin a new paragraph and insert:

"SECTION 4. IC 35-48-7-8.1, AS AMENDED BY P.L.152-2012, SECTION 14, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE UPON PASSAGE]: Sec. 8.1. (a) The board shall provide for a controlled substance prescription monitoring program that includes the following components:

(1) Each time a controlled substance designated by the board under IC 35-48-2-5 through IC 35-48-2-10 is dispensed, the dispenser shall transmit to the INSPECT program the following information:

- (A) The controlled substance recipient's name.
- (B) The controlled substance recipient's or the recipient representative's identification number or the identification number or phrase designated by the INSPECT program.
- (C) The controlled substance recipient's date of birth.
- (D) The national drug code number of the controlled substance dispensed.
- (E) The date the controlled substance is dispensed.
- (F) The quantity of the controlled substance dispensed.
- (G) The number of days of supply dispensed.
- (H) The dispenser's United States Drug Enforcement Agency registration number.
- (I) The prescriber's United States Drug Enforcement Agency registration number.
- (J) An indication as to whether the prescription was transmitted to the pharmacist orally or in writing.
- (K) Other data required by the board.

(2) The information required to be transmitted under this section must be transmitted not more than seven (7) days after the date on which a controlled substance is dispensed. **However, notwithstanding any other provision of this section, beginning:**

- (A) July 1, 2015, the information required to be transmitted under this section must be transmitted not more than three (3) days after the date on which a controlled substance is dispensed; and**



(B) January 1, 2016, the information required to be transmitted under this section must be transmitted not more than twenty-four (24) hours after the date on which a controlled substance is dispensed.

(3) A dispenser shall transmit the information required under this section by:

- (A) uploading to the INSPECT web site;
- (B) a computer diskette; or
- (C) a CD-ROM disk;

that meets specifications prescribed by the board.

(4) The board may require that prescriptions for controlled substances be written on a one (1) part form that cannot be duplicated. However, the board may not apply such a requirement to prescriptions filled at a pharmacy with a Category II permit (as described in IC 25-26-13-17) and operated by a hospital licensed under IC 16-21, or prescriptions ordered for and dispensed to bona fide enrolled patients in facilities licensed under IC 16-28. The board may not require multiple copy prescription forms for any prescriptions written. The board may not require different prescription forms for any individual drug or group of drugs. Prescription forms required under this subdivision must be approved by the Indiana board of pharmacy established by IC 25-26-13-3.

(5) The costs of the program.

(b) This subsection applies only to a retail pharmacy. A pharmacist, pharmacy technician, or person authorized by a pharmacist to dispense a controlled substance may not dispense a controlled substance to a person who is not personally known to the pharmacist, pharmacy technician, or person authorized by a pharmacist to dispense a controlled substance unless the person taking possession of the controlled substance provides documented proof of the person's identification to the pharmacist, pharmacy technician, or person authorized by a pharmacist to dispense a controlled substance.

SECTION 5. IC 35-48-7-11.1, AS AMENDED BY P.L.84-2010, SECTION 99, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE UPON PASSAGE]: Sec. 11.1. (a) Information received by the INSPECT program under section 8.1 of this chapter is confidential.

(b) The board shall carry out a program to protect the confidentiality of the information described in subsection (a). The board may disclose the information to another person only under subsection (c), (d), or (g).

(c) The board may disclose confidential information described in subsection (a) to any person who is authorized to engage in receiving,



processing, or storing the information.

(d) Except as provided in subsections (e) and (f), the board may release confidential information described in subsection (a) to the following persons:

(1) A member of the board or another governing body that licenses practitioners and is engaged in an investigation, an adjudication, or a prosecution of a violation under any state or federal law that involves a controlled substance.

(2) An investigator for the consumer protection division of the office of the attorney general, a prosecuting attorney, the attorney general, a deputy attorney general, or an investigator from the office of the attorney general, who is engaged in:

- (A) an investigation;
- (B) an adjudication; or
- (C) a prosecution;

of a violation under any state or federal law that involves a controlled substance.

(3) A law enforcement officer who is an employee of:

- (A) a local, state, or federal law enforcement agency; or
- (B) an entity that regulates controlled substances or enforces controlled substances rules or laws in another state;

that is certified to receive **controlled substance prescription drug** information from the INSPECT program.

(4) A practitioner or practitioner's agent certified to receive information from the INSPECT program.

(5) A controlled substance monitoring program in another state with which Indiana has established an interoperability agreement.

(6) The state toxicologist.

(7) A certified representative of the Medicaid retrospective and prospective drug utilization review program.

(8) A substance abuse assistance program for a licensed health care provider who:

- (A) has prescriptive authority under IC 25; and
- (B) is participating in the assistance program.

(e) Information provided to an individual under:

(1) subsection (d)(3) is limited to information:

- (A) concerning an individual or proceeding involving the unlawful diversion or misuse of a schedule II, III, IV, or V controlled substance; and
- (B) that will assist in an investigation or proceeding; and

(2) subsection (d)(4) may be released only for the purpose of:

- (A) providing medical or pharmaceutical treatment; or



(B) evaluating the need for providing medical or pharmaceutical treatment to a patient.

(f) Before the board releases confidential information under subsection (d), the applicant must be approved by the INSPECT program in a manner prescribed by the board.

(g) The board may release to:

(1) a member of the board or another governing body that licenses practitioners;

(2) an investigator for the consumer protection division of the office of the attorney general, a prosecuting attorney, the attorney general, a deputy attorney general, or an investigator from the office of the attorney general; or

(3) a law enforcement officer who is:

(A) authorized by the state police department to receive ~~the type of~~ **controlled substance prescription drug** information; ~~released;~~ and

(B) approved by the board to receive the type of information released;

confidential information generated from computer records that identifies practitioners who are prescribing or dispensing large quantities of a controlled substance.

(h) The information described in subsection (g) may not be released until it has been reviewed by:

(1) a member of the board who is licensed in the same profession as the prescribing or dispensing practitioner identified by the data;

or

(2) the board's designee;

and until that member or the designee has certified that further investigation is warranted. However, failure to comply with this subsection does not invalidate the use of any evidence that is otherwise admissible in a proceeding described in subsection (i).

(i) An investigator or a law enforcement officer receiving confidential information under subsection (c), (d), or (g) may disclose the information to a law enforcement officer or an attorney for the office of the attorney general for use as evidence in the following:

(1) A proceeding under IC 16-42-20.

(2) A proceeding under any state or federal law that involves a controlled substance.

(3) A criminal proceeding or a proceeding in juvenile court that involves a controlled substance.

(j) The board may compile statistical reports from the information described in subsection (a). The reports must not include information



that identifies any practitioner, ultimate user, or other person administering a controlled substance. Statistical reports compiled under this subsection are public records.

(k) **Except as provided in IC 25-22.5-13**, this section may not be construed to require a practitioner to obtain information about a patient from the data base.

(l) A practitioner is immune from civil liability for an injury, death, or loss to a person solely due to a practitioner seeking or not seeking information from the INSPECT program. The civil immunity described in this subsection does not extend to a practitioner if the practitioner receives information directly from the INSPECT program and then negligently misuses this information. This subsection does not apply to an act or omission that is a result of gross negligence or intentional misconduct.

(m) The board may review the records of the INSPECT program. If the board determines that a violation of the law may have occurred, the board shall notify the appropriate law enforcement agency or the relevant government body responsible for the licensure, regulation, or discipline of practitioners authorized by law to prescribe controlled substances.

(n) A practitioner who in good faith discloses information based on a report from the INSPECT program to a law enforcement agency is immune from criminal or civil liability. A practitioner that discloses information to a law enforcement agency under this subsection is presumed to have acted in good faith."

Page 4, delete lines 1 through 13, begin a new paragraph and insert:
"SECTION 6. IC 35-48-7-14 IS AMENDED TO READ AS FOLLOWS [EFFECTIVE JULY 1, 2014]: Sec. 14. A person who knowingly or intentionally violates this chapter commits a ~~Class A misdemeanor~~. **Level 6 felony**."

Page 4, line 22, after "substances." insert "**However, the board shall take into account that a dispenser does not collect the same information for a noncontrolled substance prescription and a controlled substance prescription, and the board may not require a pharmacy to collect additional information and submit information for a noncontrolled substance prescription unless the information is typically collected by a dispenser.**"

Page 4, line 24, delete "January" and insert "**July**".

Page 4, between lines 28 and 29, begin a new paragraph and insert:
"**(c) Notwithstanding any other provision of this chapter, beginning July 1, 2015, the information required to be transmitted under this section must be transmitted not more than three (3)**



days after the date on which a prescription drug is dispensed.

(d) Notwithstanding any other provision of this chapter, beginning January 1, 2016, the information required to be transmitted under this section must be transmitted not more than twenty-four (24) hours after the date on which a prescription drug is dispensed."

Page 4, line 29, delete "(c)" and insert "(e)".

Page 4, between lines 33 and 34, begin a new paragraph and insert:

"(f) This section does not apply to a facility licensed under IC 16-28 or a hospital licensed under IC 16-21 that is not required to submit prescription information under section 8.1(a)(4) of this chapter."

Renumber all SECTIONS consecutively.

and when so amended that said bill do pass.

(Reference is to HB 1218 as introduced.)

CLERE, Chair

Committee Vote: yeas 10, nays 0.

HOUSE MOTION

Mr. Speaker: I move that House Bill 1218 be amended to read as follows:

Page 1, line 11, delete "but least addictive".

Page 1, line 12, delete "drugs" and insert "**medications**".

Page 1, between lines 12 and 13, begin a new line block indented and insert:

"(2) Ensure that each patient voluntarily chooses maintenance treatment and that relevant facts concerning the use of opioid treatment medications are clearly and adequately explained to the patient."

Page 1, line 13, delete "(2)" and insert "(3)".

Page 2, line 1, delete "less addictive" and insert "**other approved**".

Page 2, line 1, delete "drugs." and insert "**medications.**".

Page 2, delete lines 2 through 5.

Page 2, line 10, delete "drugs" and insert "**medications**".

Page 2, line 10, delete "a less addictive replacement" and insert "**an alternative**".

Page 2, line 15, delete "drug" and insert "**medication**".

HB 1218—LS 6952/DI 77



Page 2, line 19, delete "drug," and insert "**medication,**".

Page 2, line 21, delete "drug." and insert "**medication.**".

Page 2, line 23, delete "drugs that are less addictive than" and insert "**medications as alternatives to**".

Page 2, line 30, delete "a controlled substance designated by" and insert "**an opioid treatment program dispenses a controlled substance designated by the Indiana board of pharmacy under IC 35-48-2-5 through 35-48-2-10, the opioid treatment program shall provide the following information upon request from the division:**

- (1) **The medications dispensed by the program.**
- (2) **The medication delivery process, which includes whether the medication was in liquid, film, or another form.**
- (3) **The number of doses dispensed of each medication.**
- (4) **The dosage quantities for each medication.**
- (5) **The number of patients receiving take home medications.**
- (6) **The number of days of supply dispensed.**
- (7) **Patient demographic information for each medication, including gender, age, and time in treatment.**
- (8) **The dispenser's United States Drug Enforcement Agency registration number."**

Page 2, delete lines 31 through 42.

Page 3, delete lines 1 through 4.

Page 7, between lines 29 and 30, begin a new paragraph and insert:
 "SECTION 5. IC 35-48-7-12.1, AS AMENDED BY P.L.42-2011, SECTION 77, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE JULY 1, 2014]: Sec. 12.1. (a) The board shall adopt rules under IC 4-22-2 to implement this chapter, including the following:

- (1) Information collection and retrieval procedures for the INSPECT program, including the controlled substances to be included in the program required under section 8.1 of this chapter.
- (2) Design for the creation of the data base required under section 10.1 of this chapter.
- (3) Requirements for the development and installation of online electronic access by the board to information collected by the INSPECT program.
- (4) Identification of emergency situations or other circumstances in which a practitioner may prescribe, dispense, and administer a prescription drug specified in section 8.1 of this chapter without a written prescription or on a form other than a form specified in section 8.1(a)(4) of this chapter.
- (5) **Requirements for a practitioner and an opioid treatment**



program operating under IC 12-23-18 to check the INSPECT program:

(A) before initially prescribing a controlled substance to a patient; and

(B) periodically during the course of treatment that uses a controlled substance.

(b) The board may:

(1) set standards for education courses for individuals authorized to use the INSPECT program;

(2) identify treatment programs for individuals addicted to controlled substances monitored by the INSPECT program; and

(3) work with impaired practitioner associations to provide intervention and treatment."

Page 8, between lines 30 and 31, begin a new paragraph and insert:

"(g) Before January 1, 2015, the Indiana professional licensing agency shall study and analyze the integrity and security of the INSPECT program concerning all controlled substances required to be reported to the INSPECT program. Notwithstanding any other provision of this section, if the Indiana professional licensing agency is unable to certify the integrity and security of the INSPECT program before January 1, 2015, the board may not accept noncontrolled substance prescription information or require the submission of noncontrolled substance prescription information until the Indiana professional licensing agency certifies to the board the integrity and security of the INSPECT program.

SECTION 8. [EFFECTIVE JULY 1, 2014] **(a) During the 2014 interim of the general assembly, the health finance commission (IC 2-5-23) shall study the integrity and security of the INSPECT program (IC 35-48-7). The commission shall make findings and recommendations, including recommendations to the Indiana professional licensing agency established by IC 25-1-5-3 to ensure that data collected by the INSPECT program may be used only for lawful purposes.**

(b) This SECTION expires January 1, 2015."

Renumber all SECTIONS consecutively.

(Reference is to HB 1218 as printed January 24, 2014.)

CLERE

